imiquimod has been researched along with tazarotene in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bowen, AR; Herron, MD; Krueger, GG | 1 |
| Fenske, NA; Glass, LF; Prakash, AV; Shistik, G | 1 |
| Jacobs, AA; McClung, A; Modi, G; Orengo, IF; Rosen, T | 1 |
| Anolik, R; Brightman, L; Geronemus, R; Warycha, M | 1 |
| Bowen, GM; Goldgar, D; Hadley, ML; Hyde, MA; Tristani-Firouzi, P | 1 |
| Dou, W; Hu, J; Sun, J; Zhao, Y | 1 |
| Apalla, Z; Chan, AW; Kyrgidis, A; Mocellin, S; Pilati, P; Tzellos, T | 1 |
| Bowen, GM; Bowling, M; Donigan, JM; Goldgar, DE; Hadley, ML; Hyde, MA | 1 |
| Baker, C; Chambers, M; Chapman, MS; Saunders, E; Swetter, SM | 1 |
| Liu, Y; Luo, S; Wang, H; Xi, C; Xiong, C | 1 |
2 review(s) available for imiquimod and tazarotene
| Article | Year |
|---|---|
Do lasers or topicals really work for nonmelanoma skin cancers?
Topics: Administration, Cutaneous; Aminoquinolines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Chemexfoliation; Dermatologic Agents; Fluorouracil; Humans; Imiquimod; Laser Therapy; Nicotinic Acids; Paget Disease, Extramammary; Photochemotherapy; Skin Neoplasms | 2011 |
Interventions for melanoma in situ, including lentigo maligna.
Topics: Aminoquinolines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Male; Melanoma; Melanoma, Cutaneous Malignant; Nicotinic Acids; Randomized Controlled Trials as Topic; Skin Neoplasms | 2014 |
2 trial(s) available for imiquimod and tazarotene
| Article | Year |
|---|---|
Seborrheic keratoses: a study comparing the standard cryosurgery with topical calcipotriene, topical tazarotene, and topical imiquimod.
Topics: Adjuvants, Immunologic; Administration, Topical; Aged; Aminoquinolines; Calcitriol; Cryosurgery; Dermatologic Agents; Drug Administration Schedule; Female; Humans; Imiquimod; Keratosis, Seborrheic; Male; Middle Aged; Nicotinic Acids; Pilot Projects; Retinoids; Treatment Outcome | 2004 |
A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Biopsy; Cheek; Dermatologic Agents; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Gels; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Middle Aged; Mohs Surgery; Nicotinic Acids; Off-Label Use; Ointments; Postoperative Care; Prospective Studies; Skin Neoplasms; Treatment Outcome | 2012 |
7 other study(ies) available for imiquimod and tazarotene
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Treatment of locally metastatic melanoma: a novel approach.
Topics: Administration, Cutaneous; Aged, 80 and over; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Imiquimod; Melanoma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nicotinic Acids; Skin Neoplasms; Treatment Outcome | 2007 |
Combination therapy with imiquimod, 5-fluorouracil, and tazarotene in the treatment of extensive radiation-induced Bowen's disease of the hands.
Topics: Aminoquinolines; Antineoplastic Agents; Biopsy; Bowen's Disease; Dermatologic Agents; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Therapy, Combination; Fluorouracil; Follow-Up Studies; Hand; Humans; Imiquimod; Male; Middle Aged; Neoplasms, Radiation-Induced; Nicotinic Acids; Skin Neoplasms | 2010 |
A comparison of the effects of topical treatment of calcipotriol, camptothecin, clobetasol and tazarotene on an imiquimod-induced psoriasis-like mouse model.
Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Animals; Anti-Inflammatory Agents; Calcitriol; Camptothecin; Clobetasol; Dermatologic Agents; Disease Models, Animal; Humans; Imiquimod; Mice; Mice, Inbred BALB C; Nicotinic Acids; Psoriasis; Topoisomerase I Inhibitors | 2014 |
Rate of Recurrence of Lentigo Maligna Treated With Off-Label Neoadjuvant Topical Imiquimod, 5%, Cream Prior to Conservatively Staged Excision.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Female; Follow-Up Studies; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Nicotinic Acids; Off-Label Use; Retrospective Studies; Skin Neoplasms; Treatment Outcome | 2018 |
Topical Imiquimod for Lentigo Maligna: Survival Analysis of 103 Cases With 17 Years Follow-up.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Follow-Up Studies; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Keratolytic Agents; Male; Middle Aged; Neoplasm Recurrence, Local; Nicotinic Acids; Prospective Studies; Retrospective Studies; Skin Neoplasms; Time Factors | 2021 |
Combination of retinoids and narrow-band ultraviolet B inhibits matrix metalloproteinase 13 expression in HaCaT keratinocytes and a mouse model of psoriasis.
Topics: Animals; Cell Line; Cell Proliferation; Disease Models, Animal; HaCaT Cells; Humans; Imiquimod; Keratinocytes; Matrix Metalloproteinase 13; Mice; Nicotinic Acids; Psoriasis; Retinoids; Ultraviolet Rays; Ultraviolet Therapy | 2021 |